Clinical Trials Directory

Trials / Completed

CompletedNCT00930631

Study of [3H] BMS747158 in Healthy Male Subjects

Pharmacokinetics, Metabolism and Elimination of Tritiated [3H] BMS747158 in Healthy Male Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
7 (actual)
Sponsor
Lantheus Medical Imaging · Industry
Sex
Male
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The purpose of this clinical study is to assess the safety, extent and route of \[3H\] BMS747158 radioactivity eliminated (mass balance) in urine and feces of healthy male subjects. The safety of \[3H\] BMS747158 administration will also be assessed, as well as pharmacokinetics of \[3H\] BMS747158 and metabolite identification.

Detailed description

This Phase I, nonrandomized, open-label study will enroll up to seven healthy male subjects who meet all of the inclusion and none of the exclusion criteria. Subjects will receive 100 (±20) μCi of \[3H\] BMS747158. Subjects will undergo blood, urine, and fecal collections to evaluate \[3H\] activity for a minimum of 7 days post-dose. Safety will be assessed by monitoring of adverse events (AEs), vital signs, physical examinations, clinical laboratory tests, and electrocardiograms (ECGs).This Phase I, nonrandomized, open-label study will enroll up to seven healthy male subjects who meet all of the inclusion and none of the exclusion criteria. Subjects will receive 100 (±20) μCi of \[3H\] BMS747158. Subjects will undergo blood, urine, and fecal collections to evaluate \[3H\] activity for a minimum of 7 days post-dose. Safety will be assessed by monitoring of adverse events (AEs), vital signs, physical examinations, clinical laboratory tests, and electrocardiograms (ECGs).

Conditions

Interventions

TypeNameDescription
DRUG[3H] BMS747158Single bolus intravenous injection of \[3H\] BMS747158

Timeline

Start date
2009-06-01
Primary completion
2009-07-01
Completion
2010-01-01
First posted
2009-06-30
Last updated
2020-11-10

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00930631. Inclusion in this directory is not an endorsement.